We develop ADCs and radioligands, leveraging our conjugation platform. We create new treatments ofefring hope to patients that suffer from aggressive cancer with poor prognosis.

Products, services, technology

The CIS Biopharma AG pipeline, developed by the team, comprises:

CBO-001, a full-length antibody targeting L1CAM / CD-171
CBO-002, a nanobody targeting B7-H3 / CD-276
CBO-003, a polymer-based drug-carrier technology platform

Cooperation possibilities

We collaborate with patient organizations, clinics, physicians, scientists and financial partners to advance breakthrough technology in cancer therapy.

Some insights
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in